Tumor mutations in ASCL1, a driver of advanced neuroendocrine prostate cancer,60MBD2, an epigenetic regulator that binds methylated DNA,61,62 and the RBP FXR163,64 each increase the half-lives of their respective oncogenic mRNAs, establishing these as functional oncogenic 3′ UTR mutations (Figure 3B, chr18:54154901 T→A, chr12:102960501 T→A, and chr3:180978239 A→G, respectively). This evidence concerns the gene ASCL1 and neoplasm.